Close
In July, researchers from the UK DRI at UCL, including Prof Nick Fox, Prof John Hardy, Prof Bart De Strooper and Dr Frances Wiseman, headed to Amsterdam for the Alzheimer’s Association International Conference (AAIC) 2023. The major event spanned four days, and scientists heard the latest developments in dementia research through a fantastic programme of talks, panel events and networking opportunities.
The highlight of the week for many was the reveal of the full results from the phase three trial of new Alzheimer’s drug donanemab. There was palpable excitement in the room as the data was presented, and the news has been hailed as a significant breakthrough. The results show that the drug significantly slows the progression of the disease in people with early symptomatic Alzheimer’s disease.
Prof John Hardy, Group Leader at the UK DRI at UCL, spoke to BBC News live from the conference, to discuss just how significant these results are.